NO972426L - Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose - Google Patents

Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose

Info

Publication number
NO972426L
NO972426L NO972426A NO972426A NO972426L NO 972426 L NO972426 L NO 972426L NO 972426 A NO972426 A NO 972426A NO 972426 A NO972426 A NO 972426A NO 972426 L NO972426 L NO 972426L
Authority
NO
Norway
Prior art keywords
osteoporosis
prevention
treatment
derivatives
triarylethylene
Prior art date
Application number
NO972426A
Other languages
English (en)
Other versions
NO972426D0 (no
Inventor
Alan Joseph Bitonti
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/531,885 external-priority patent/US5691384A/en
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of NO972426D0 publication Critical patent/NO972426D0/no
Publication of NO972426L publication Critical patent/NO972426L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en metode for anvendelse av triaryl-ethylenderivater ved behand- ling eller hindring av benvevtap eller osteoporose.
NO972426A 1994-11-29 1997-05-28 Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose NO972426L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34611194A 1994-11-29 1994-11-29
US08/531,885 US5691384A (en) 1994-11-29 1995-10-11 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
PCT/US1995/013873 WO1996016646A1 (en) 1994-11-29 1995-10-27 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis

Publications (2)

Publication Number Publication Date
NO972426D0 NO972426D0 (no) 1997-05-28
NO972426L true NO972426L (no) 1997-07-29

Family

ID=26994698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972426A NO972426L (no) 1994-11-29 1997-05-28 Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose

Country Status (12)

Country Link
US (1) US5693674A (no)
EP (1) EP0794771A1 (no)
JP (1) JPH10509962A (no)
CN (1) CN1167437A (no)
AU (1) AU707290B2 (no)
CA (1) CA2206422A1 (no)
FI (1) FI972235A0 (no)
HU (1) HUT77603A (no)
IL (1) IL116142A0 (no)
MX (1) MX9703944A (no)
NO (1) NO972426L (no)
WO (1) WO1996016646A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
CN101448490A (zh) * 2006-05-22 2009-06-03 霍尔莫斯医疗有限公司 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂
EP2121553B1 (en) * 2007-02-14 2012-06-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
EP2307342B1 (en) 2008-07-02 2017-06-21 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法
WO2016112455A1 (en) * 2015-01-13 2016-07-21 British Columbia Cancer Agency Branch Heterocyclic compounds for cancer imaging and treatment and methods for their use
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CA3115101A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP4135675A4 (en) 2020-04-17 2024-04-10 Essa Pharma, Inc. SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
US3247252A (en) * 1962-11-14 1966-04-19 Richardson Merrell Inc Beta-dialkylaminoethylamino-triphenylethanols, -ethanes, and -ethenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1128379A (en) * 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
US4001229A (en) * 1974-04-04 1977-01-04 Mead Johnson & Company Alkanesulfonamido triphenylethylenes
DE2860900D1 (en) * 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
JPH06312930A (ja) * 1993-04-30 1994-11-08 Kuraray Co Ltd 骨粗鬆症治療剤
US5525633A (en) * 1993-09-24 1996-06-11 Merrell Dow Pharmaceuticals Inc. Triaryl-ethylene derivatives
NZ272608A (en) * 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts

Also Published As

Publication number Publication date
MX9703944A (es) 1998-05-31
JPH10509962A (ja) 1998-09-29
IL116142A0 (en) 1996-01-31
WO1996016646A1 (en) 1996-06-06
AU707290B2 (en) 1999-07-08
HUT77603A (hu) 1998-06-29
NO972426D0 (no) 1997-05-28
CA2206422A1 (en) 1996-06-06
US5693674A (en) 1997-12-02
FI972235A (fi) 1997-05-27
AU4196796A (en) 1996-06-19
CN1167437A (zh) 1997-12-10
FI972235A0 (fi) 1997-05-27
EP0794771A1 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
NO981810D0 (no) Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt
NO972426L (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
DE69638351D1 (de) Sowie zur resektion des distalen und vorderen femurs
GB9407135D0 (en) Treatment of osteoporosis
DE69524365D1 (de) Verfahren zur Isolierung und Reinigung von 2'-Deoxy-2',2'-difluornucleosiden
NO982311D0 (no) Sammensetninger og fremgangsmÕter for forhindring og behandling av oral mukositt
NO20056021L (no) Anvendelse av CS-866 til fremstilling av et medikament
TR199802441A3 (tr) Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.
NO965563D0 (no) Behandling og profylakse av osteoporese
NO962482D0 (no) Anordning og fremgangsmåte ved behandling av organohalogen forbindelser
PL321835A1 (en) Method of reducing the risk of non-vertebral bone fracture
ZA931778B (en) Method and composition for the treatment of osteoporosis
NO962752D0 (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
PL339762A1 (en) Method of cleaning surgical instruments
PL321836A1 (en) Method of reducing the risk of vertebral bone fracture
NO982582L (no) Fremgangsmaate for behandling av smerte
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
NO985695D0 (no) Formulering og fremgangsmÕte for Õ behandle kongrestiv hjerteinfarkt
EP0763143A4 (en) METHOD FOR TREATING TITANIUM PARTS
EP0692965A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS
DE69413325D1 (de) 24-Epi-1alpha-Hydroxyvitamin D2 zur Behandlung von Osteoporosis
IL129431A0 (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
ZA9510062B (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
NO911010D0 (no) Fremgangsmaate for behandling av svovel-, jern- og sinkholdige metallurgiske biprodukter og/eller avfallsprodukter.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application